FIELD: medicine.
SUBSTANCE: method is implemented by introducing a composition containing an effective amount of interfering RNA of the length of 19-27 nucleotides, and a pharmaceutically acceptable carrier wherein interfering RNA contains a sense nucleotide chain, and an antisense nucleotide chain wherein a complementary™ site makes at least 19 continuous nucleotides. There are also presented methods of treating a TNF-α related condition in a subject in need thereof, and a composition for treating the TNF-α related eye condition.
EFFECT: invention may be effectively used in treating the patients suffering a TNF-α related condition or having a risk of such developing condition.
23 cl, 1 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDIATED PHKi INHIBITION OF Rho-KINASE FOR TREATING OPHTHALMIC DISORDERS | 2006 |
|
RU2432165C2 |
| TREATMENT OF CNS DISORDERS | 2007 |
|
RU2426544C2 |
| TREATMENT OF DISEASES ASSOCIATED WITH ERYTHROPOIETIN (EPO) BY NATURAL EPO ANTISENSE TRANSCRIPT INHIBITION | 2009 |
|
RU2620970C2 |
| TREATING SIRTIUN 1 (SIRT1)-RELATED DISEASES BY INHIBITON OF NATURAL ANTISENSE TRANSCRIPT | 2009 |
|
RU2551234C2 |
| TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) ASSOCIATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1 | 2011 |
|
RU2611195C2 |
| HSP47 EXPRESSION MODULATION | 2010 |
|
RU2575056C2 |
| METHODS FOR TREATMENT OF HEPATITIS B INFECTION | 2018 |
|
RU2780021C2 |
| TREATMENT OF DISEASES RELATED WITH GENE DLG BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT OF DLG GENE | 2011 |
|
RU2611190C2 |
| TREATMENT OF ALPHA-L-IDURONIDASE (IDUA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IDUA | 2011 |
|
RU2597972C2 |
| siPHK-BASED TREATMENT OF EYE DISEASE CHARACTERISED BY HIGH INTRAOCULAR PRESSURE | 2005 |
|
RU2407531C2 |
